NCT03463187 - Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions

Moderate-to-severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL

SHR-1314

Administered subcutaneously

DRUG

Placebo

Administered subcutaneously

Trial Locations (13)

2145

Westmead Hospital, Westmead

2217

St George Dermatology and Skin Cancer Centre - Dermatology, Kogarah

3002

Sinclair Dermatology - Dermatology, East Melbourne

4102

Veracity Clinical Research Pty Ltd, Woolloongabba

33012

Indago Research and Health Center - Emergency Medicine, Hialeah

33122

Revival Research, Doral

60640

Great Lakes Clinical Trials LLC, Chicago

77004

Center for Clinical Studies, Houston

77598

Center for Clinical Studies, Webster

85018

Elite Clinical Studies, LLC, Phoenix

92801

Anaheim Clinical Trials, Anaheim

200040

Shanghai Huanshan Hospital Fudan University-Dermatology, Shanghai

02919

Clinical Partners, LLC, Johnston

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY